 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...188189190191192193194195196197198...235236» |
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial termination, PD(L)-1 Biomarker, IO biomarker: A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach (clinicaltrials.gov) - Aug 10, 2017
P2, N=40, Terminated, Sponsor: Weijing Sun, MD, FACP
IND withdrawn & revised protocol submitted through the new institution. New study recruiting under NCT03488667.
- |||| BMS-813160 / BMS, Opdivo (nivolumab) / BMS
Enrollment open: A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Aug 10, 2017
P1b/2, N=260, Recruiting, Sponsor: Bristol-Myers Squibb
New study recruiting under NCT03488667. Not yet recruiting --> Recruiting
- | gemcitabine / Generic mfg.
Journal: Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. (Pubmed Central) - Aug 10, 2017
Not yet recruiting --> Recruiting Within NAPOLI-1, nal-IRI+5-FU/LV resulted in statistically significant and clinically meaningful gains in quality-adjusted survival vs 5-FU/LV alone.
- | Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Journal: FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Advanced Pancreatic Cancer: A Brown University Oncology Research Group Phase I Study. (Pubmed Central) - Aug 10, 2017
The maximum tolerated dose of nab-paclitaxel is 150 mg/m every 2 weeks with FOLFOX. The regimen of FOLFOX-A represents a promising treatment for pancreatic cancer.
- | Mekinist (trametinib) / Novartis, BeiGene
Trial primary completion date, Surgery, Metastases: SWOG-S1310: Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery (clinicaltrials.gov) - Aug 10, 2017
P2, N=52, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
The regimen of FOLFOX-A represents a promising treatment for pancreatic cancer. Trial primary completion date: Jul 2016 --> Jan 2017
- | Avastin (bevacizumab) / Roche
New trial, Metastases: A Pilot Study of Neoadjuvant Chemotherapy Combined With Bevacizumab for Locally Advanced Rectal Cancer (clinicaltrials.gov) - Aug 9, 2017
P=N/A, N=70, Not yet recruiting, Sponsor: Chinese PLA General Hospital
- | AiTan (rivoceranib) / HLB Bio Group
New P1 trial: Phase I Study of the Combination of Apatinib and POF (clinicaltrials.gov) - Aug 9, 2017
P1, N=9, Not yet recruiting, Sponsor: Fujian Cancer Hospital
- | Trial primary completion date: Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer (clinicaltrials.gov) - Aug 9, 2017
P3, N=2000, Active, not recruiting, Sponsor: Hellenic Oncology Research Group
Trial primary completion date: Jul 2016 --> Jan 2017 Trial primary completion date: May 2017 --> Nov 2017
- ||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial initiation date, Metastases: AIO-NIFE-trial: Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer (clinicaltrials.gov) - Aug 9, 2017
P2, N=92, Not yet recruiting, Sponsor: AIO-Studien-gGmbH
Trial primary completion date: May 2017 --> Nov 2017 Initiation date: May 2017 --> Nov 2017
- | Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly
Enrollment open, Combination therapy, Metastases: Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial. (clinicaltrials.gov) - Aug 9, 2017
P2, N=43, Recruiting, Sponsor: AIO-Studien-gGmbH
Initiation date: May 2017 --> Nov 2017 Not yet recruiting --> Recruiting
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date, Surgery, Metastases: PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery (clinicaltrials.gov) - Aug 8, 2017
P2/3, N=1060, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2017 --> Jan 2021
- | saridegib oral (IPI 926 oral) / Infinity Pharma
Trial completion, Enrollment change, Trial initiation date, Trial primary completion date, Metastases: FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Aug 8, 2017
P1, N=15, Completed, Sponsor: Andrew Ko
Trial primary completion date: Jul 2017 --> Jan 2021 Recruiting --> Completed | N=21 --> 15 | Initiation date: Nov 2014 --> Aug 2011 | Trial primary completion date: Nov 2017 --> Dec 2012
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date, Metastases: FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma (clinicaltrials.gov) - Aug 7, 2017
P2, N=66, Recruiting, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Completed | N=21 --> 15 | Initiation date: Nov 2014 --> Aug 2011 | Trial primary completion date: Nov 2017 --> Dec 2012 Trial primary completion date: Apr 2017 --> Oct 2018
- | Bavencio (avelumab) / EMD Serono
Trial suspension, Combination therapy, Metastases: Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 (clinicaltrials.gov) - Aug 7, 2017
P2, N=81, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Apr 2017 --> Oct 2018 Recruiting --> Suspended
- | Avastin (bevacizumab) / Roche
Journal: Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma. (Pubmed Central) - Aug 3, 2017
First-line mFOLFOX6 with bevacizumab for metastatic gastroesophageal adenocarcinoma was well tolerated and associated with longer PFS and OS compared with historical data from similar populations treated without bevacizumab. Our results suggest that the addition of bevacizumab to mFOLFOX6 may provide clinical benefit in American patients with metastatic gastroesophageal adenocarcinoma, a finding consistent with previous studies of first-line bevacizumab in combination with chemotherapy for this disease.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial completion: ATOM: Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (clinicaltrials.gov) - Aug 2, 2017
P2, N=122, Completed, Sponsor: EPS Corporation
Our results suggest that the addition of bevacizumab to mFOLFOX6 may provide clinical benefit in American patients with metastatic gastroesophageal adenocarcinoma, a finding consistent with previous studies of first-line bevacizumab in combination with chemotherapy for this disease. Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Biomarker, Trial completion: ATOM ES: Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (clinicaltrials.gov) - Aug 2, 2017
P=N/A, N=110, Completed, Sponsor: EPS Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Enrollment open: Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma (clinicaltrials.gov) - Aug 2, 2017
P2, N=28, Recruiting, Sponsor: Yale University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Trial primary completion date: A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma (clinicaltrials.gov) - Aug 1, 2017
P2, N=50, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2017 --> Apr 2018
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial primary completion date, Circulating tumor cells, Tumor cell, Metastases: VISNU-2: Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC) (clinicaltrials.gov) - Aug 1, 2017
P2, N=240, Active, not recruiting, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Trial primary completion date: Apr 2017 --> Apr 2018 Trial primary completion date: Jun 2017 --> Nov 2018
- |||| Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: VISNU-1: Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells (clinicaltrials.gov) - Aug 1, 2017
P3, N=350, Active, not recruiting, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Trial primary completion date: Jun 2017 --> Nov 2018 Trial primary completion date: Jun 2017 --> Nov 2018
- | Avastin (bevacizumab) / Roche
Trial initiation date, Trial primary completion date: ORCHESTRA: Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases (clinicaltrials.gov) - Aug 1, 2017
P=N/A, N=478, Recruiting, Sponsor: VU University Medical Center
Trial primary completion date: Jun 2017 --> Nov 2018 Initiation date: Dec 2012 --> May 2013 | Trial primary completion date: Jul 2017 --> Dec 2018
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Trial primary completion date: FOXAGAST: NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma (clinicaltrials.gov) - Aug 1, 2017
P2, N=55, Recruiting, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Initiation date: Dec 2012 --> May 2013 | Trial primary completion date: Jul 2017 --> Dec 2018 Trial primary completion date: Jun 2017 --> Oct 2017
- | Enrollment change, Metastases: SYLT: POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC (clinicaltrials.gov) - Aug 1, 2017
P2, N=90, Enrolling by invitation, Sponsor: Fujian Cancer Hospital
Trial primary completion date: Jun 2017 --> Oct 2017 N=30 --> 90
- | oxaliplatin / Generic mfg., cisplatin / Generic mfg., gemcitabine / Generic mfg.
Trial primary completion date, Metastases: ABC06: Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers (clinicaltrials.gov) - Jul 31, 2017
P3, N=162, Recruiting, Sponsor: The Christie NHS Foundation Trust
N=30 --> 90 Trial primary completion date: Jan 2018 --> Nov 2018
- conatumumab (AMG 655) / Amgen
Trial primary completion date: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) - Jul 31, 2017
P2, N=12, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Jan 2018 --> Nov 2018 Trial primary completion date: Jul 2017 --> Jan 2018
- | Stivarga (regorafenib) / Bayer
Trial initiation date, Monotherapy, Metastases: Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC (clinicaltrials.gov) - Jul 31, 2017
P2, N=15, Not yet recruiting, Sponsor: Fox Chase Cancer Center
Trial primary completion date: Jul 2017 --> Jan 2018 Initiation date: Jun 2017 --> Oct 2017
- | Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Journal: Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. (Pubmed Central) - Jul 29, 2017
Follow-up visits every 3 to 4 months are recommended. Additional information is available at www.asco.org/guidelines/LAPC and www.asco.org/guidelines/MetPC and www.asco.org/guidelineswiki.
- | erlotinib / Generic mfg., Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Journal: Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. (Pubmed Central) - Jul 29, 2017
For second-line therapy, gemcitabine plus NAB-paclitaxel should be offered to patients with first-line treatment with FOLFIRINOX, an ECOG PS 0 to 1, and a favorable comorbidity profile; fluorouracil plus oxaliplatin, irinotecan, or nanoliposomal irinotecan should be offered to patients with first-line treatment with gemcitabine plus NAB-paclitaxel, ECOG PS 0 to 1, and favorable comorbidity profile, and gemcitabine or fluorouracil should be offered to patients with either an ECOG PS 2 or a comorbidity profile that precludes other regimens. Additional information is available at www.asco.org/guidelines/MetPC and www.asco.org/guidelineswiki.
- | leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
Journal: Chemotherapy Pharmacodynamics and Neuroimaging and Neurocognitive Outcomes in Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia. (Pubmed Central) - Jul 29, 2017
Survivors of childhood acute lymphoblastic leukemia treated on contemporary chemotherapy-only protocols demonstrate executive dysfunction. A higher plasma concentration of methotrexate was associated with executive dysfunction as well as with a thicker cortex and higher activity in frontal brain regions, regions often associated with executive function.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. (Pubmed Central) - Jul 29, 2017
In combination with cetuximab, ECF and FOLFOX had similar efficacy, but FOLFOX was better tolerated. Although differences were nonsignificant, IC plus cetuximab seemed to be the least effective and most toxic of the three regimens tested.
- |||||| Decadron (dexamethasone) / Merck (MSD), Oncaspar liquid (pegaspargase) / Servier
Enrollment open, Trial primary completion date: DFCI 16-001: Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents (clinicaltrials.gov) - Jul 28, 2017
P3, N=400, Recruiting, Sponsor: Dana-Farber Cancer Institute
Although differences were nonsignificant, IC plus cetuximab seemed to be the least effective and most toxic of the three regimens tested. Not yet recruiting --> Recruiting | Trial primary completion date: May 2021 --> Dec 2021
- | Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: AXEPT: A Phase III Study of 2nd-line XELIRI (clinicaltrials.gov) - Jul 27, 2017
P3, N=650, Active, not recruiting, Sponsor: Epidemiological and Clinical Research Information Network
Not yet recruiting --> Recruiting | Trial primary completion date: May 2021 --> Dec 2021 Trial primary completion date: Jan 2017 --> Nov 2017
- | Otrexup (methotrexate) / Halozyme, Rituxan (rituximab) / Roche
Trial primary completion date: Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma (clinicaltrials.gov) - Jul 21, 2017
P2, N=28, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2017 --> Nov 2017 Trial primary completion date: Jul 2018 --> Jul 2019
- | 5-fluorouracil / Generic mfg., metformin / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date, Metastases: Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jul 19, 2017
P2, N=43, Recruiting, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Jul 2018 --> Jul 2019 Trial primary completion date: Apr 2017 --> Oct 2017
- | Enrollment open: FOLOXIRIREC: FOLFOXIRI Chemotherapy Alone as Neoadjuvant Treatment for Circumferential Radial Margin (CRM) Positive Rectal Cancer (clinicaltrials.gov) - Jul 19, 2017
P2, N=32, Enrolling by invitation, Sponsor: Guangxi Medical University
Trial primary completion date: Apr 2017 --> Oct 2017 Not yet recruiting --> Enrolling by invitation
- | New P2 trial, Combination therapy, Metastases: Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC (clinicaltrials.gov) - Jul 19, 2017
P2, N=60, Not yet recruiting, Sponsor: Fujian Cancer Hospital
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
New P3 trial: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) (clinicaltrials.gov) - Jul 18, 2017
P3, N=800, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- ||||| locnartecan (PEN-866) - Tarveda Therap, National Cancer Institute / Bethesda
New P1/2 trial, Metastases: PEN-866 in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - Jul 18, 2017
P1/2, N=150, Recruiting, Sponsor: Tarveda Therapeutics
- | Arzerra (ofatumumab) / Novartis, Genmab, Rituxan (rituximab) / Roche
Trial completion, Trial primary completion date: Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients (clinicaltrials.gov) - Jul 17, 2017
P2, N=77, Completed, Sponsor: Polish Lymphoma Research Group
Not yet recruiting --> Enrolling by invitation Recruiting --> Completed | Trial primary completion date: Oct 2017 --> Jul 2017
- || simmitecan / HaiHe Biopharma, Shanghai Inst. of Materia Medica
Enrollment change, Trial primary completion date, Monotherapy, Metastases: Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jul 17, 2017
P1, N=243, Recruiting, Sponsor: ShangHai HaiHe Pharmaceutical
Recruiting --> Completed | Trial primary completion date: Oct 2017 --> Jul 2017 N=158 --> 243 | Trial primary completion date: Oct 2018 --> Dec 2020
- | otilimab (GSK3196165) / GSK
Enrollment closed, Trial primary completion date, Combination therapy: Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis (clinicaltrials.gov) - Jul 17, 2017
P2a, N=40, Active, not recruiting, Sponsor: GlaxoSmithKline
N=158 --> 243 | Trial primary completion date: Oct 2018 --> Dec 2020 Recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> Oct 2017
- | thioguanine / Generic mfg., azacitidine / Generic mfg.
Phase classification: AALL15P1: Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement (clinicaltrials.gov) - Jul 16, 2017
P2, N=116, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> Oct 2017 Phase classification: P1 --> P2
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. (Pubmed Central) - Jul 15, 2017
P3
Among patients with KRAS wt untreated advanced or metastatic colorectal cancer, there was no significant difference in overall survival between the addition of cetuximab vs bevacizumab to chemotherapy as initial biologic treatment. clinicaltrials.gov identifier: NCT00265850.
- ||| Enrollment change: OPRA: Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management (clinicaltrials.gov) - Jul 13, 2017
P2, N=300, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
clinicaltrials.gov identifier: NCT00265850. N=222 --> 300
- | Enrollment change, Trial primary completion date: CALGB-80803: PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy (clinicaltrials.gov) - Jul 13, 2017
P2, N=257, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
N=222 --> 300 N=204 --> 257 | Trial primary completion date: Jun 2017 --> Nov 2015
- || dilpacimab (ABT-165) / AbbVie
Enrollment closed, Trial primary completion date, Metastases: A Study of ABT-165 in Subjects With Solid Tumors (clinicaltrials.gov) - Jul 13, 2017
P1, N=90, Active, not recruiting, Sponsor: AbbVie
N=204 --> 257 | Trial primary completion date: Jun 2017 --> Nov 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Feb 2018
- || Trial primary completion date: OPRA: Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management (clinicaltrials.gov) - Jul 12, 2017
P2, N=222, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Feb 2018 Trial primary completion date: Nov 2017 --> Nov 2018
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Enrollment closed, Trial primary completion date: FFCD 1201 DEBIRI: Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study (clinicaltrials.gov) - Jul 11, 2017
P2, N=58, Active, not recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
Trial primary completion date: Nov 2017 --> Nov 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Jan 2018
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma (clinicaltrials.gov) - Jul 11, 2017
P1, N=21, Recruiting, Sponsor: University of California, Davis
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Jan 2018 Trial primary completion date: Dec 2016 --> Dec 2017